These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24051927)
1. Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor. Bariani GM; Carvalheira JB; Riechelmann RP Onkologie; 2013; 36(9):502-4. PubMed ID: 24051927 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749 [TBL] [Abstract][Full Text] [Related]
3. Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. Pusceddu S; Milione M; Procopio G Oncol Res; 2011; 19(8-9):403-6. PubMed ID: 22329200 [TBL] [Abstract][Full Text] [Related]
4. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report. Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634 [TBL] [Abstract][Full Text] [Related]
5. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Flaum N; Valle JW; Mansoor W; McNamara MG Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069 [TBL] [Abstract][Full Text] [Related]
6. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. Thompson LA; Kim M; Wenger SD; O'Bryant CL Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595 [TBL] [Abstract][Full Text] [Related]
7. Role of everolimus in pancreatic neuroendocrine tumors. Goldstein R; Meyer T Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937 [TBL] [Abstract][Full Text] [Related]
8. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Chan HY; Grossman AB; Bukowski RM Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133 [TBL] [Abstract][Full Text] [Related]
12. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Peng L; Schwarz RE Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005 [TBL] [Abstract][Full Text] [Related]
13. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266 [TBL] [Abstract][Full Text] [Related]
14. Targeted agents in treatment of neuroendocrine tumors of pancreas. Karampelas IN; Syrigos KN; Saif MW JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341 [TBL] [Abstract][Full Text] [Related]
16. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role? Barna ME; Uomo I; Pastorello M JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347 [No Abstract] [Full Text] [Related]
17. New target therapies for patients with neuroendocrine tumors of the pancreas. Baltogiannis G; Katsios C; Roukos DH Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571 [No Abstract] [Full Text] [Related]
18. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410 [TBL] [Abstract][Full Text] [Related]
19. Everolimus for the treatment of pancreatic neuroendocrine tumors. Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789 [TBL] [Abstract][Full Text] [Related]
20. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report. Asayama M; Yamada-Murano T; Hara H; Ooki A; Kurosumi M; Yamaguchi K Jpn J Clin Oncol; 2014 Feb; 44(2):186-90. PubMed ID: 24367043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]